GenoMed’s Results Supported by Canadian Study: Dose is Key!


David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938

ST. LOUIS—February 12, 2009—GenoMed® (OTC Pink Sheets GMED.PK) announced today that AstraZeneca’s study showing that high dose Atacand was better than low dose drug for patients with kidney failure fully supports results its CEO observed 15 years earlier.

Yesterday, AstraZeneca released results from a study using high dose Atacand (candesartan) in patients spilling protein in their urine ( Although the patients were unresponsive to 16 mg a day, they responded well to a dose 8 times greater, 128 mg a day.

GenoMed’s CEO, David Moskowitz MD, noticed a similar phenomenon beginning in 1994. Patients who progressed rapidly to dialysis on the conventional dose of ACE inhibitor reversed their kidney failure when the dose was increased sufficiently. The only dose-dependent side effect, high serum potassium, could be easily controlled using a second medication. Not all ACE inhibitor drugs were equivalent, however, and ARBs added little.

Dr. Moskowitz published these results in 2002. They form the basis for GenoMed’s Next Generation Disease Management service for patients with diabetes or high blood pressure.

Said Dr. Moskowitz, “It’s been over six years since we published our results in a peer-reviewed journal. We could have kept 90% of America’s current 300,000 dialysis and transplant patients out of trouble if our paper had received the slightest press attention. The healthcare system’s ongoing failure to embrace a cure that affects tens of millions of people is a public health tragedy of global proportions. My only conclusion is that disease itself has become too lucrative for the healthcare system to allow its elimination. Any attempt to reform the healthcare system must take into account its fundamental corruption over the past half century.”

About GenoMed

GenoMed published how to prevent 90% of kidney failure in 2002. The company’s “recipe” is the subject of a pending patent, good in the US. GenoMed is now marketing its Next Generation Disease Management service globally to patients with diabetes or high blood pressure. Please contact GenoMed at or

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.